Modality
Peptide
MOA
DLL3 ADC
Target
PRMT5
Pathway
mTOR
LN
Development Pipeline
Preclinical
~May 2020
→ ~Aug 2021
Phase 1
Nov 2021
→ May 2030
Phase 1Current
NCT04467238
1,465 pts·LN
2021-11→2030-05·Active
NCT04938962
1,415 pts·LN
2024-11→2028-11·Active
2,880 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2028-11-242.7y awayInterim· LN
2030-05-074.1y awayInterim· LN
Trial Timeline
Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3
P1
Active
P1
Active
Catalysts
Interim
2028-11-24 · 2.7y away
LN
Interim
2030-05-07 · 4.1y away
LN
Active|StartCompletionToday
Trials (2)
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Nirarelsin | Johnson & Johnson | Phase 2 | PRMT5 | |
| NVS-4076 | Novartis | Preclinical | TROP-2 | |
| MRK-853 | Merck & Co | Phase 1 | PRMT5 | |
| Rimamavacamten | Merck & Co | Phase 1 | PI3Kα | |
| Geliderotide | Sanofi | Phase 1/2 | PRMT5 | |
| Capifutibatinib | Sanofi | Approved | PRMT5 | |
| NVO-9615 | Novo Nordisk | Phase 2/3 | PRMT5 | |
| Suracagene | GSK | Phase 3 | PRMT5 | |
| AMG-9654 | Amgen | Phase 2 | GPRC5D | |
| Elrarapivir | Vertex Pharma | NDA/BLA | PRMT5 |